Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
c19early.org COVID-19 treatment researchNiclosamideNiclosamide (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

 
    
  
Niclosamide for COVID-19
6 studies from 45 scientists
2,091 patients in 5 countries
Significantly lower risk for recovery.
2 studies from 2 independent teams in 2 countries show significant benefit.
COVID-19 Niclosamide studies. Dec 2024. c19early.org
0 0.5 1 1.5+ All studies 21% With exclusions 22% Mortality 14% Hospitalization 13% Recovery 30% Cases -2% Viral clearance 1% RCTs 21% RCT mortality 14% Prophylaxis 0% Early 37% Late 21% Favorsniclosamide Favorscontrol
Dec 23
Covid Analysis Niclosamide for COVID-19: real-time meta analysis of 6 studies
Significantly lower risk is seen for recovery. 2 studies from 2 independent teams in 2 countries show significant benefit. Meta analysis using the most serious outcome reported shows 21% [-47‑57%] lower risk, without reaching s..
Nov 21
Haque et al., Discover Molecules, doi:10.1007/s44345-024-00005-5 Exploring potential therapeutic candidates against COVID-19: a molecular docking study
In Silico study showing potential inhibition of SARS-CoV-2 proteins by various compounds including dactinomycin, itraconazole, ivermectin, vitamin D, quercetin, curcumin, montelukast, bromhexine, hesperidin, EGCG and raloxifene. Authors p..
Aug 6
Rank et al., NCT04603924 A Phase 2/3 Randomized and Placebo-Controlled Study of ANA001 in Moderate and Severe COVID-19 Patients
36% lower mortality (p=0.67), 70% faster recovery (p=0.97), 57% higher hospital discharge (p=0.98), and no change in viral clearance (p=1). RCT 46 moderate to severe hospitalized COVID-19 patients showing shorter time to discharge and WHO clinical scale improvement with niclosamide, but no significant difference for resolution of all symptoms and viral clearance.
Jun 19
Pejler et al., Journal of Allergy and Clinical Immunology, doi:10.1016/j.jaci.2024.05.031 Blockade of endolysosomal acidification suppresses TLR3-mediated pro-inflammatory signaling in airway epithelial cells
In Vitro study showing that blocking endolysosomal acidification with bafilomycin A1, monensin, or niclosamide suppresses TLR3-mediated pro-inflammatory signaling in human small airway epithelial cells (HSAECs) stimulated with TLR3 agonis..
May 6
Walther et al., medRxiv, doi:10.1101/2024.05.06.24306928 Clinical safety and pharmacokinetics of a novel oral niclosamide formulation compared with marketed niclosamide chewing tablets in healthy volunteers: a three-part randomized, double-blind, placebo-controlled trial
Phase 1 trial of 28 healthy volunteers showing an investigational niclosamide solution was reasonably well-tolerated up to 1,600mg for 7 days, with no severe adverse events. The most common adverse events were mild to moderate gastrointes..
Mar 29
Siripongboonsitti et al., Journal of Infection and Public Health, doi:10.1016/j.jiph.2024.03.030 A Randomized Trial to Assess the Acceleration of Viral Clearance by the Combination Favipiravir/Ivermectin/Niclosamide in Mild-to-Moderate COVID-19 Adult Patients (FINCOV)
39% improved recovery (p=0.19) and 6% improved viral clearance (p=0.75). RCT 60 low-risk outpatients, median age 31, with mild to moderate COVID-19 showing no significant differences with combined favipiravir/ivermectin/niclosamide treatment compared to favipiravir alone. There was limited room for improvement..
Mar 14
Wannigama et al., eClinicalMedicine, 10.1016/j.eclinm.2024.102517 Early treatment with fluvoxamine, bromhexine, cyproheptadine, and niclosamide to prevent clinical deterioration in patients with symptomatic COVID-19: a randomized clinical trial
98% lower ventilation (p<0.0001), 100% lower need for oxygen therapy (p<0.0001), 98% lower hospitalization (p<0.0001), and 59% lower PASC (p<0.0001). RCT 995 outpatients showing significantly lower progression with early treatment within 48 hours using fluvoxamine, fluvoxamine+bromhexine, fluvoxamine+cyproheptadine, and niclosamide+bromhexine. 70% of patients received treatment within ..
Mar 6
Walia et al., Nature Communications, doi:10.1038/s41467-024-46417-2 SARS-CoV-2 virulence factor ORF3a blocks lysosome function by modulating TBC1D5-dependent Rab7 GTPase cycle
In Vitro study showing that SARS-CoV-2 ORF3a protein hyperactivates the Rab7 GTPase to block lysosomal degradation and promote viral replication. Authors found that the chemical compound CID-1067700, a Rab7 inhibitor, reduced SARS-CoV-2 r..
Oct 11
2023
Garrett et al., Frontiers in Microbiology, doi:10.3389/fmicb.2023.1251065 Niclosamide as a chemical probe for analyzing SARS-CoV-2 modulation of host cell lipid metabolism
In Vitro study showing that niclosamide modulates host lipid metabolism and reduces infectious SARS-CoV-2 virion production in Vero E6 cells. Authors observed reorganization of the lipid profile in infected cells, with increased triglycer..
Sep 20
2023
Ali et al., Journal of Clinical Medicine, doi:10.3390/jcm12186079 SARS-CoV-2 Syncytium under the Radar: Molecular Insights of the Spike-Induced Syncytia and Potential Strategies to Limit SARS-CoV-2 Replication
Review of the molecular mechanisms of SARS-CoV-2 spike-induced syncytia formation and potential anti-fusogenic therapeutic strategies. The SARS-CoV-2 spike protein interacts with the ACE2 receptor on adjacent cells, triggering abnormal fu..
Jul 26
2023
Humphrey et al., Elsevier BV, doi:10.2139/ssrn.4519538 Prophylaxis for Patients at Risk of COVID-19 Infection: Results from the Intranasal Niclosamide Randomised, Double Blinded, Placebo Controlled Arm of the PROTECT-V Platform Trial
80% lower ventilation (p=0.25), 13% lower hospitalization (p=0.71), and 2% more symptomatic cases (p=0.89). RCT 1,651 patients with kidney disease showing no significant difference in symptomatic COVID-19, hospitalization, or mortality with intranasal niclosamide compared to placebo. The UNI911 nasal spray had very poor adherence and a higher w..
Jul 18
2023
Yang et al., Biomedicines, doi:10.3390/biomedicines11072019 Repurposing Niclosamide as a Novel Anti-SARS-CoV-2 Drug by Restricting Entry Protein CD147
In Vitro study showing that niclosamide reduces CD147 protein levels and inhibits SARS-CoV-2-induced upregulation of CD147 in A549-ACE2 cells. Authors find that the RNA-binding protein HuR binds to the 3'-UTR of BSG mRNA and upregulates C..
Jul 1
2023
Sheng et al., Acta Biochimica et Biophysica Sinica, doi:10.3724/abbs.2023129 A pseudovirus-based method to dynamically mimic SARS-CoV-2-associated cell-to-cell fusion and transmission
In Vitro study showing that niclosamide dramatically blocked the formation of syncytia mediated by SARS-CoV-2 spike protein pseudovirus-producing 293FT cells when cocultured with hACE2-expressing 293T cells at 1μM concentration. Authors d..
May 1
2023
First Wave BioPharma, NCT04858425 A 2-Part, 2-Arm, Phase 2, Randomized, Double-Blind, Placebo-Controlled Study on the Safety and Efficacy of Niclosamide in Patients With COVID-19 With Gastrointestinal Infection
23% improved viral clearance (p=0.61). RCT 118 hospitalized patients with gastrointestinal infection showing no significant difference in viral clearance with niclosamide. Viral clearance results are available on clinicaltrials.gov but clinical results are missing.
Jan 7
2023
Vibhute et al., International Journal of Applied Pharmaceutics, doi:10.22159/ijap.2023v15i1.45850 Niclosamide: a potential treatment option for COVID-19
Review of niclosamide as a potential treatment option for COVID-19. Authors report antiviral activity against SARS-CoV-2 in vitro, with an IC50 of 0.28 μM. However, the currently available oral formulations limit systemic levels. To impro..
Dec 1
2022
Abed et al., Journal of Pharmaceutical Technolgy, doi:10.37662/jpt.2022.999481 Evaluation the plausibility of repurpose of levamisole and niclosamide in treatment of covid-19
Review of the plausibility of repurposing levamisole and niclosamide for treatment of COVID-19. Niclosamide, an FDA-approved antihelminthic drug, has shown antiviral activity against various viruses including SARS-CoV, MERS-CoV, and poten..
Aug 9
2022
Wotring et al., Vaccines, doi:10.3390/vaccines10081284 In Vitro Evaluation and Mitigation of Niclosamide’s Liabilities as a COVID-19 Treatment
In Vitro study suggesting that niclosamide has variable potency against SARS-CoV-2 variants and may have cytotoxicity concerns and significant polypharmacology. Authors found that niclosamide inhibited SARS-CoV-2 infection in VeroE6 and H..
Jun 18
2022
Jitobaom et al., BMC Pharmacology and Toxicology, doi:10.1186/s40360-022-00580-8 (date from preprint) Synergistic anti-SARS-CoV-2 activity of repurposed anti-parasitic drug combinations
In Vitro study showing a strong synergistic effect of combinations of ivermectin, niclosamide, and chloroquine, with >10x reduction in IC50 compared to individual drugs.
Apr 20
2022
Cesar-Silva et al., International Journal of Molecular Sciences, doi:10.3390/ijms23094576 The Endolysosomal System: The Acid Test for SARS-CoV-2
Review of the role of the endolysosomal system in SARS-CoV-2 infection. The endolysosomal system, which includes endosomes and lysosomes, is crucial for cellular homeostasis and host defense against pathogens. SARS-CoV-2 can enter cells b..
Apr 11
2022
Singh et al., British Journal of Pharmacology, doi:10.1111/bph.15843 Niclosamide—A promising treatment for COVID‐19
Review of niclosamide as a promising treatment for COVID-19. Authors highlight niclosamide's potent antiviral activity against SARS-CoV-2 and its pleiotropic anti-inflammatory, antibacterial, bronchodilatory and anticancer effects demonst..
Feb 9
2022
Cairns et al., JAMA Network Open, doi:10.1001/jamanetworkopen.2021.44942 Efficacy of Niclosamide vs Placebo in SARS-CoV-2 Respiratory Viral Clearance, Viral Shedding, and Duration of Symptoms Among Patients With Mild to Moderate COVID-19
18% faster recovery (p=0.28) and 24% improved viral clearance (p=0.45). RCT with 73 mild to moderate outpatients, showing faster recovery and improved viral clearance with niclosamide, without statistical significance. Greater improvements in recovery were seen for high-risk patients, again without statistica..
Dec 28
2021
Needham, D., Pharmaceutical Research, doi:10.1007/s11095-021-03112-x The pH Dependence of Niclosamide Solubility, Dissolution, and Morphology: Motivation for Potentially Universal Mucin-Penetrating Nasal and Throat Sprays for COVID19, its Variants and other Viral Infections
In Vitro study showing that niclosamide has potential as a prophylactic nasal spray and early treatment throat spray for COVID-19 and other respiratory viral infections. Authors find that niclosamide's solubility and dissolution rate are..
Oct 18
2021
Al-kuraishy et al., Molecular Biology Reports, doi:10.1007/s11033-021-06770-7 Niclosamide for Covid-19: bridging the gap
Review of niclosamide as a potential treatment for COVID-19. Authors highlight the anti-inflammatory and antiviral effects of niclosamide, which modulates the release of pro-inflammatory cytokines, inhibits the NF-κB/NLRP3 inflammasome an..
Sep 30
2021
Abdulamir et al., Annals of Medicine & Surgery, doi:10.1016/j.amsu.2021.102779 A randomised controlled trial of effectiveness and safety of Niclosamide as add on therapy to the standard of care measures in COVID-19 management
39% improved recovery (p=0.007). RCT with 75 COVID-19 patients showing significantly faster recovery but no change in mortality with niclosamide. The treatment group had more patients aged 60+ and more patients treated over a week after symptom onset.
Jun 16
2021
Munson et al., British Society For Nanomedicine Early Career Researcher Summer Meeting, 2021 Niclosamide and ivermectin modulate caspase-1 activity and proinflammatory cytokine secretion in a monocytic cell line
In Vitro study showing potential therapeutic effects of ivermectin and niclosamide on the immune system by reducing inflammation and modulating key proteins involved in the inflammatory response. Ivermectin and niclosamide reduced proinfl..
Feb 14
2021
Erenmemisoglu et al., NCT04558021 A Phase III, Randomized, Placebo-controlled, Clinical Trial to Evaluate the Efficacy and Safety of Co-administered Niclosamide in Patients Treated With an Established Regimen for Novel Coronavirus Infectious Disease (COVID-19)
Estimated 200 patient niclosamide late treatment RCT with results not reported over 3 years after estimated completion.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit